{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:47:56Z","timestamp":1767134876999,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006007.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T00:00:00Z","timestamp":1433808000000}}],"reference-count":81,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006007.pub4","type":"journal-article","created":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T17:19:28Z","timestamp":1433956768000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease"],"prefix":"10.1002","volume":"2015","author":[{"given":"Arturo J","family":"Mart\u00ed-Carvajal","sequence":"first","affiliation":[{"name":"Iberoamerican Cochrane Network; Valencia Venezuela"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Sol\u00e0","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 171 - Edifici Casa de Convalesc\u00e8ncia Barcelona Catalunya Spain 08041"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,9]]},"reference":[{"key":"10.1002\/14651858.CD006007.pub4-BIB0001|cit1","unstructured":"Colle I Wilmer A Le Moine O Debruyne R Delwaide J Dhondt E Upper gastrointestinal tract bleeding management: Belgian guidelines for adults and children Acta Gastro-Enterologica Belgica 2011 45 66"},{"issue":"11","key":"10.1002\/14651858.CD006007.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1111\/j.1572-0241.2000.03299.x","article-title":"Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease","volume":"95","author":"Agarwal","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/bmj.328.7438.476","article-title":"Absence of evidence is not evidence of absence","volume":"328","author":"Alderson","year":"2004","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-2002-23205","article-title":"Coagulation disorders in liver disease","volume":"22","author":"Amitrano","year":"2002","journal-title":"Seminars in Liver Disease"},{"issue":"4","key":"10.1002\/14651858.CD006007.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD006007.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1258\/ebm.2011.011255","article-title":"Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism","volume":"237","author":"Beier","year":"2012","journal-title":"Experimental Biology and Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006007.pub4-BIB0007|cit7","first-page":"250","article-title":"Primary hyperfibrinolysis in liver disease: a critical review","volume":"9","author":"Bennani-Baiti","year":"2011","journal-title":"Clinical Advances in Hematology & Oncology"},{"issue":"8","key":"10.1002\/14651858.CD006007.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD006007.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"7572","key":"10.1002\/14651858.CD006007.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","article-title":"How to formulate research recommendations","volume":"333","author":"Brown","year":"2006","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","article-title":"Molecular mechanisms of fibrinolysis","volume":"129","author":"Cesarman-Maus","year":"2005","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/bmj.328.7438.475","article-title":"Well informed uncertainties about the effects of treatments","volume":"328","author":"Chalmers","year":"2004","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0013|cit13","first-page":"e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1002\/14651858.CD006007.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00062752-200211000-00014","article-title":"Transfusion-sparing hemostatic agents","volume":"9","author":"Chiu","year":"2002","journal-title":"Current Opinion in Hematology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/jhep.2003.50277","article-title":"Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis","volume":"38","author":"Colucci","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0017|cit17","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.thromres.2007.07.008","article-title":"Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency","volume":"121","author":"Ferguson","year":"2008","journal-title":"Thrombosis Research"},{"issue":"15","key":"10.1002\/14651858.CD006007.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.2014.11100","article-title":"The PCORI perspective on patient-centered outcomes research","volume":"312","author":"Frank","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0020|cit20","unstructured":"Gluud C Nikolova D Klingenberg SL Cochrane Hepato-Biliary Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2015, Issue 3. Art. No.: LIVER"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2036.2006.02730.x","article-title":"The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis","volume":"23","author":"Gunawan","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD006007.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD006007.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD006007.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD006007.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD006007.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence - publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD006007.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD006007.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence - inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD006007.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence - indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD006007.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Guyatt GH Oxman AD Santesso N Helfand M Vist G Kunz R GRADE guidelines 12. Preparing summary of findings tables-binary outcomes Journal of Clinical Epidemiology 2013 158 72","DOI":"10.1016\/j.jclinepi.2012.01.012"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"Guyatt G Oxman AD Sultan S Brozek J Glasziou P Alonso-Coello P GRADE guidelines 11 - making an overall rating of confidence in effect estimates for a single outcome and for all outcomes Journal of Clinical Epidemiology 2013 151 7","DOI":"10.1016\/j.jclinepi.2012.01.006"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000057299","article-title":"General haemostatic agents - fact or fiction?","volume":"32 Suppl 1","author":"Hedner","year":"2002","journal-title":"Pathophysiology of Haemostasis and Thrombosis"},{"issue":"6681","key":"10.1002\/14651858.CD006007.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/bmj.298.6681.1142","article-title":"Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage","volume":"298","author":"Henry","year":"1989","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"7414","key":"10.1002\/14651858.CD006007.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0036|cit36","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0037|cit37","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1572-0241.2001.03781.x","article-title":"Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit","volume":"96","author":"Hu","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0039|cit39","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"3-4","key":"10.1002\/14651858.CD006007.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jrsm.19","article-title":"The art of getting it wrong","volume":"1","author":"Ioannidis","year":"2010","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2288-14-34","article-title":"The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"9","key":"10.1002\/14651858.CD006007.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2174\/138920111798281036","article-title":"Fibrinolytic factors in liver fibrosis","volume":"12","author":"Kang","year":"2011","journal-title":"Current Pharmaceutical Biotechnology"},{"issue":"6","key":"10.1002\/14651858.CD006007.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1476-4431.2011.00691.x","article-title":"Coagulation in hepatobiliary disease","volume":"21","author":"Kavanagh","year":"2011","journal-title":"Journal of Veterinary Emergency and Critical Care"},{"issue":"11","key":"10.1002\/14651858.CD006007.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD006007.pub4-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub2","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006007.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM199807233390407","article-title":"Hemostatic drugs","volume":"339","author":"Mannucci","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006007.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11209070-000000000-00000","article-title":"Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis","volume":"72","author":"McCormack","year":"2012","journal-title":"Drugs"},{"issue":"9128","key":"10.1002\/14651858.CD006007.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0051|cit51","first-page":"466","article-title":"The incidence of consumption coagulopathy in liver cirrhosis","volume":"6","author":"Moreno Abad\u00eda","year":"1989","journal-title":"Anales de Medicina Interna"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.510310214","article-title":"Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices","volume":"31","author":"Piscaglia","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1111\/j.1572-0241.2001.05298.x","article-title":"Liver cirrhosis, ascites, and hyperfibrinolysis","volume":"96","author":"Piscaglia","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD006007.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2478\/v10039-010-0018-3","article-title":"Coagulopathy in liver diseases","volume":"55","author":"Pluta","year":"2010","journal-title":"Advances in Medical Sciences"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0055|cit55","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"4","key":"10.1002\/14651858.CD006007.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.08021.x","article-title":"Haemostasis and thrombosis in liver disease","volume":"148","author":"Roberts","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"35","key":"10.1002\/14651858.CD006007.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD006007.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006007.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD006007.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/pop.2013.1621","article-title":"The patient-centered outcomes research institute: a 2013 agenda for \"research done differently\"","volume":"16","author":"Selby","year":"2013","journal-title":"Population Health Management"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Selby JV Patient-Centered Outcomes Research Institute seeks to find out what works best by involving 'end-users' from the beginning Journal of Comparative Effectiveness Research 2014 125 9","DOI":"10.2217\/cer.13.94"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD006007.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0064|cit64","first-page":"57","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"Thorlund","year":"2010","journal-title":"Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0065|cit65","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual for trial sequential analysis (TSA), 2011 ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"issue":"2","key":"10.1002\/14651858.CD006007.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The coagulopathy of chronic liver disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0067|cit67","unstructured":"Copenhagen Trial Unit TSA - trial sequential analysis 2011"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0068|cit68","first-page":"153","article-title":"Coagulation disorders in cirrhosis","volume":"59","author":"T\u00e9llez-Avila","year":"2007","journal-title":"Revista de Investigaci\u00f3n Cl\u00ednica"},{"issue":"4","key":"10.1002\/14651858.CD006007.pub4-BIB0069|cit69","first-page":"433","article-title":"Hemostasis in patients with liver disease","volume":"72","author":"Werf","year":"2009","journal-title":"Acta Gastro-Enterologica Belgica"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bpg.2007.10.011","article-title":"Epidemiology of acute upper gastrointestinal bleeding","volume":"22","author":"Leerdam","year":"2008","journal-title":"Best Practice & Research. Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0071|cit71","first-page":"67","article-title":"Coagulation and fibrinolysis in individuals with advanced liver disease","volume":"15","author":"Thiel","year":"2004","journal-title":"Turkish Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/hep.1840150420","article-title":"Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis","volume":"15","author":"Violi","year":"1992","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hep.1840170115","article-title":"Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation abnormalities in liver cirrhosis","volume":"17","author":"Violi","year":"1993","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD006007.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2011.06.008","article-title":"Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?","volume":"55","author":"Violi","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD006007.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"7644","key":"10.1002\/14651858.CD006007.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD006007.pub4-BIB0078|cit78","unstructured":"Universidad de Carabobo Zavala D, Mart\u00ed A, Pe\u00f1a-Mart\u00ed G, Comuni\u00e1n G. Sheet to enter data for performing a Cochrane review 2006"},{"issue":"2","key":"10.1002\/14651858.CD006007.pub4-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006007","article-title":"Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease","author":"Marti-Carvajal","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006007.pub4-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006007.pub2","article-title":"Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease","author":"Mart\u00ed-Carvajal","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD006007.pub4-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006007.pub3","article-title":"Antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease","author":"Mart\u00ed-Carvajal","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006007.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T05:20:44Z","timestamp":1725945644000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006007.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,9]]},"references-count":81,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006007.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,9]]}}}